Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00137332|
Recruitment Status : Terminated
First Posted : August 29, 2005
Last Update Posted : December 10, 2007
|Condition or disease||Intervention/treatment||Phase|
|Arrhythmia||Drug: GAP-486 (ZP-123) Drug: 0.9% Sodium Chloride, USP||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Study of the Effects GAP-486 on Ventricular Tachyarrhythmia Induction|
|Study Start Date :||November 2005|
|Study Completion Date :||October 2006|
U.S. FDA Resources
- The measure to determine the effect of the intervention will be whether abnormally fast heart rhythm can be induced after test drug is administered.
- This study takes place within 24 hours, and looks at whether the test article makes a difference in inducing the abnormally fast heart rhythm during a 24 hour observational period.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00137332
Show 33 Study Locations
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|